Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine.

Abstract

The 1986-87 outbreak of paralytic poliomyelitis in Senegal, with 676 reported cases, provided an opportunity to evaluate the efficacy of an enhanced-potency inactivated poliovirus vaccine (N-IPV) in the Kolda region, where this vaccine has been used since 1980. 89 cases, confirmed to have poliomyelitis with residual paralysis, were enrolled in a case-control study, up to 5 matched controls being obtained for each case. The clinical efficacy for one dose of N-IPV was 36% (95% confidence interval 0%, 67%) and for two doses was 89% (95% CI 62%, 97%).

• Authors: S E Robertson, H P Traverso, J A Drucker, E Z Rovira, B Fabre-Teste, A Sow, M N'Diaye, M T Sy, F Diouf
• Journal: Lancet (London, England) (Lancet) Vol. 1 Issue 8591 Pg. 897-9 (Apr 23 1988) ISSN: 0140-6736 [Print] England
• PMID: 2895828 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• DTPP vaccine
• Diphtheria Toxoid
• Diphtheria-Tetanus-Pertussis Vaccine
• Drug Combinations
• Pertussis Vaccine
• Poliovirus Vaccine, Inactivated
• Tetanus Toxoid
• Vaccines, Attenuated
• Vaccines, Combined

Topics

• Adolescent
• Adult
• Child
• Child, Preschool
• Diphtheria Toxoid (administration & dosage, immunology, standards)
• Diphtheria-Tetanus-Pertussis Vaccine
• Disease Outbreaks (prevention & control)
• Drug Combinations (administration & dosage, immunology, standards)
• Epidemiologic Methods
• Female
• Humans
• Immunization Schedule
• Infant
• Pertussis Vaccine (administration & dosage, immunology, standards)
• Pilot Projects
• Poliomyelitis (complications, epidemiology, prevention & control)
• Poliovirus Vaccine, Inactivated (administration & dosage, immunology, standards)
• Rural Population
• Seasons
• Senegal
• Tetanus Toxoid (administration & dosage, immunology, standards)
• Vaccines, Attenuated (administration & dosage, immunology, standards)
• Vaccines, Combined